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Abstract: Simultaneous visualization and concentration quan-
tification of molecules in biological tissue is an important
though challenging goal. The advantages of fluorescence
lifetime imaging microscopy (FLIM) for visualization, and
electron paramagnetic resonance (EPR) spectroscopy for
quantification are complementary. Their combination in
a multiplexed approach promises a successful but ambitious
strategy because of spin label-mediated fluorescence quench-
ing. Here, we solved this problem and present the molecular
design of a dual label (DL) compound comprising a highly
fluorescent dye together with an EPR spin probe, which also
renders the fluorescence lifetime to be concentration sensitive.
The DL can easily be coupled to the biomolecule of choice,
enabling in vivo and in vitro applications. This novel approach
paves the way for elegant studies ranging from fundamental
biological investigations to preclinical drug research, as shown
in proof-of-principle penetration experiments in human skin
ex vivo.
Introduction
The quantification of molecules of interest in tissue
usually requires invasive procedures, including time-consum-
ing steps of tissue homogenization, and performing analysis
such as chemical extraction of the sample. Current methods in
preclinical research often lack a proof of translatability to
human,[1] which contributes to the poor success rates in
clinical studies. Method validation is thereby often neglected
while found to be essential as the real concentration at the
target site remains unknown.[1] Therefore, spectroscopic
techniques for direct, non-invasive, and spatially resolved
concentration quantification are highly desirable. While EPR
allows to quantify the absolute number of spin-labeled
molecules in tissue without homogenization and extraction,
as shown for nanocarriers and drugs in skin,[2] it has a limited
spatial resolution of approximately 50–100 mm.[3] The use of
conventional fluorescence microscopy as a direct quantitative
tool for concentration determination in tissue has been
explored but remains challenging, except in certain cases,[4]
mostly due to scattering and absorption of the excitation and
the emitted fluorescence light, as well as the autofluorescence
in the tissue.[5] However, fluorescence lifetime imaging
microscopy (FLIM) has received a lot of attention in the
recent years as a sensitive tool for visualizing the spatial
distribution of endogenous and exogenous fluorescent mol-
ecules at the subcellular and suborganelle level.[6] This
sensitivity and signal specificity of FLIM relies on the
fluorescence lifetime as an intrinsic property of a given
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fluorophore that is usually independent of fluorophore
concentration and optical loss in the sample,[7] and inter alia
provides discrimination between background fluorescence
from molecules that naturally reside in tissue and the target
fluorescence.[5d, 8] Moreover, fluorescence lifetime is sensitive
to the environment,[6b,c,9] as is EPR.[10] EPR provides infor-
mation about the surrounding microenvironment of the spin-
labeled molecule, such as polarity, pH, and viscosity, which
can be inferred from the spectral shape, hyperfine coupling
constant, g-tensor, and rotational correlation time of the EPR
signal.[2, 10,11] The changes in fluorescence lifetime offer insight
into the microenvironment of the fluorophore, including pH,
polarity, viscosity, biomolecular interactions, or reactive oxy-
gen species.[6, 9] However, this environmental sensitivity may
also interfere with concentration determination in FLIM.
Up to now, the biomolecule of interest in general is singly
labeled: a fluorophore label for studying biomolecular
dynamics and interactions,[9a,d, 12] or visualization and tissue
distribution by FLIM;[6c,9c,13] and a spin label for quantifica-
tion of target molecules in tissue or their dynamics by
EPR.[2,10, 11, 14] However, individual labeling of the molecule of
interest with a fluorophore or spin label could change its
physicochemical properties, such as the logP (log octanol–
water partition coefficient) value, and thereby tissue pene-
tration.[15] Combining the strength of FLIM and EPR, we
envisioned a dual label (DL) for multiplexed FLIM and EPR
measurements (Figure 1) overcoming those risks.
Herein, we developed a general platform for synthesizing
a dual label compound (DL), which realizes the simultaneous
investigation by FLIM and EPR. We present the design,
synthesis and photophysical properties of DL. The major
challenge for a dual fluorescence–spin label is fluorescence
deactivation by the unpaired electron of the spin label,
a process which is usually employed in fluorescence quench-
ing studies.[9e,16] We show that in contrast to other tested spin
label–fluorescent dye combinations, such as fluorescein and 3-
Carboxy-Proxyl (PCA), the combination of Rhodamine B
(RhoB) and PCA (Figure 2) yields high fluorescence and spin
probe stability. Very importantly, upon PCA conjugation
RhoB is turned into a concentration dependent fluorescence
lifetime probe.
The characterization of this RhoB containing DL is
further accompanied by proof-of-principle experiments in
skin tissue—a tissue that is highly relevant in topical drug
application and the development of dermal and transdermal
drug delivery systems.[2, 13b, 17] In the aged population, tissues
including skin and mucous membranes of the oral cavity are
prone to tumors,[9f,18] but 96% of anticancer drug candidates
from preclinical studies fail in human.[19] DL labeling for
insight into spatially resolved tissue concentrations quantified
by EPR and FLIM offers an approach to method validation.[1]
In particular, preclinical drug development will take signifi-
cant profit from a larger spectrum of analytical methods with
high spatial resolution and responding to concentration and
environmental changes.
The experiments in tissue-mimicking agarose gel samples
as well as in skin tissue revealed a highly consistent
determination of DL concentration by both techniques, and
the spatial distribution of DL in different tissue layers.
Furthermore, the combination of EPR and FLIM in multi-
Figure 1. Fluorescence label (Rhodamine B, RhoB) properties, intensity
and fluorescence lifetime, can be tuned to be both true concentration
sensitive when in conjugation with a spin label (3-carboxy-proxyl,
PCA). Colors mark the read-out parameters of each label. The resulting
dual label (DL) probe provides non-destructive target detection and
quantification as well as characterization of local environment in tissue
via FLIM and EPR. Besides tissue applications, a DL-labeled biomole-
cule enables in vitro spectroscopic studies of the biomolecular con-
formation, structure, and dynamics.
Figure 2. Scheme of DL synthesis. PCA (3) and Rhodamine B-piperazine (5) were covalently linked to Fmoc-Lys(Boc)-OH (1) yielding the DL
conjugate (6). (2) deprotected Lys(Boc)-OH, (4) Boc-Lys-PCA.
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plexed FLIM–EPR experiments enabled us to evaluate the
microenvironments of the DL in the different tissue layers.
Thus, our novel platform for dual-labeled compounds will
provide unprecedented insight into the tissue distribution of
biomolecules, their concentration and microenvironment due
to multiplexed FLIM and EPR spectroscopy, both in funda-
mental and applied research.
Results and Discussion
To develop a dual fluorescence-spin label compound for
accurate concentration determination and simultaneous vis-
ualization of molecules in tissue (Figure 1), we first had to
establish a platform for synthesizing the DL. We describe the
synthesis and characterization of the tri-functional linker that
contains the spin label PCA, a fluorescent molecule, and
a third open labeling position for the conjugation to
a biomolecule, drug or nanocarrier of choice. As shown in
Figure 2, the synthesis can be split into two general processes:
a) activation and conjugation of PCA and b) modification and
conjugation of a fluorescent dye (the fully detailed synthesis
conditions of each step can be found in the SI Experimental
procedures). Both, the conjugation of PCA and the dye to
lysine were conducted via a stable amide linkage. In the first
step, after Fmoc deprotection of 1 according to literature
(95 % yield),[20] the NHS (N-hydroxysuccinimide)-activated
PCA (3) was introduced via amide bond formation to give 4 as
a yellow oil (81 % yield). In the next step a fluorescent dye is
covalently attached to 4. In a first trial, 6-amino-fluorescein
was attached through an amide bond to the carboxylic acid of
compound 4, expecting that the covalent attachment of 6-
aminofluorescein yields a fluorescent conjugate.[21] Unfortu-
nately, neither fluorescence increase upon attachment nor an
active spin-probe were observed (Figure S1). This may be due
to quenching effects on the reactions of the PCA radical by
the aminofluorescein derivative. For a successful fluorescence
labeling, we used a piperazine linker between the fluorophore
and the spin probe. RhoB was functionalized with piperazine
(5) to allow stable amide bond formation with the COOH
group of lysine and to avoid pH-driven cyclization that forms
a non-fluorescent adduct. The functionalization of 5 was
performed using EDC (ethylene dichloride)-HCl, DIPEA
(diisopropylethylamine), and HOBt (1-hydroxybenzotrazole
hydrate), during 16 h reaction at room temperature. Further-
more, the fluorescent dye was covalently attached to 4. The
DL (6) was obtained as a purple solid (76 % yield) after
chromatographic purification. Importantly, the tert-butanol
ester bond in the DL provides the third labeling position, after
deprotection. All characteristic signals of DL were identified
in the 1H NMR and mass spectra (Figure S2–11). The logP-
value (log octanol–water partition coefficient) of 0.07: 0.05
for DL reveals good water solubility. Furthermore, we
demonstrated the stability of DL against endogenous tissue
enzymes (Figure S12, Table S1).
In Figure 3, we present the spectroscopic characterization
of the DL and its precursors in aqueous solution. The addition
of the piperazine linker to RhoB at its carboxy-phenyl group
(RhoB-pip, 5) leads to a bathochromic shift compared to the
RhoB spectrum, yielding an absorbance maximum at labs =
(567: 1) nm and an emission maximum at lem = (592: 1) nm
(Figure 3A, B). A decrease of the fluorescence decay time
from t = 1.7 ns for RhoB[22] to t = 1.49 ns for RhoB-pip (5)
was observed (Figure 3C, Figure S13, Table S2) and consis-
tent with known effects on RhoB emission, quantum yield,
and fluorescence lifetime depending on the condition of the
carboxy-phenyl group.[23] The addition of the Boc-Lys linker
and PCA changed the absorption, emission, and fluorescence
only slightly (Figure 3A–C, Table S2). DL exhibits a labs =
(566: 1) nm and lem = (590: 1) nm (Figure 3 A, B), a fluo-
rescence lifetime of t = 1.41 ns (Figure 3C, Table S2), and
a quantum yield f = 0.18: 0.03 in water, which was deter-
mined using RhoB in ethanol[23a] as reference. The main
reduction of RhoB fluorescence in aqueous solution stems
from the conjugation to the piperazine linker (Figure 3B).
Compared to the RhoB fluorescence, the DL fluorescence is
reduced only by a factor of about two (Figure 3B), taking the
respective extinction coefficients of RhoB and DL into
Figure 3. Characterization of DL in phosphate-buffered saline (PBS)
solution and in cryosections from tissue mimetics (agarose gels).
A) Normalized absorbance spectra of Rhodamine B (RhoB), DL (6),
Rhodamine B-piperazine (5), and Boc-Lys-RhoB-piperazine for compar-
ison. B) Emission spectra of the compounds shown in (A) at 10 or
12.6 mM (DL). C) Fluorescence decay curves of the compounds shown
in (A). D) EPR spectra of 504 mM DL (6) and PCA dissolved in PBS.
The correlation time is given. E) Concentration dependence of the
fluorescence intensity of RhoB and DL from tissue mimetics using
FLIM. F) Concentration dependence of the fluorescence lifetime of
RhoB and DL in cryosections from tissue mimetics using FLIM. The
errors bars are : SD (n = 3).
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account (SI Experimental procedures). Thus, DL exhibits
good fluorescence in phosphate buffered saline (PBS).
Figure 3D shows the EPR spectra of DL and PCA alone.
The spectra exhibit the typical three peaks of the nitroxide
spin, meaning that the chemical synthesis did not destroy the
unpaired electron of PCA. A quantitative EPR analysis
reveals about 60% of the spin labels being active after DL
synthesis (SI Experimental Procedures, Figure S14, S15).
Since stability tests of the spin label (Figure S16) show no
further losses, the DL concentrations from EPR in Figure 4F–
H were calculated by taking the 60% active spin label into
account (see SI Experimental procedures). The high magnetic
field peak of DL had a lower peak-to-peak height in
comparison to the unlabeled PCA (Figure 3D). By simulating
the EPR spectra of PCA and DL (see SI Experimental
procedures), the rotational correlation time of DL was about
ten times slower than for PCA free in solution, indicating that
the mobility of PCA in the DL was reduced because of the
neighboring covalently bound Fmoc or RhoB moiety. Taken
together, the results shown in Figure 3 demonstrate the
establishment of a novel platform to synthesize a functional
dual fluorescence-spin label probe.
Next, we performed proof-of-principle experiments in
human skin. The determination of DL concentration in skin
via fluorescence requires the following two factors to be
known: a) the stability of DL upon incubation with skin, and
b) the correlation of fluorescence intensity and lifetime with
DL concentration. We investigated the DL stability by
comparing the absorbance and emission of the DL solution
under conditions mimicking the skin penetration experiment
(Figure S17). We found a decrease in fluorescence intensity
over time upon the exposure of the DL solution to normal air,
probably due to oxidation. Fluorescence intensity of the DL
decreased by a factor of Fr = 1.8 after 2 h of incubation at
32 8C, while the fluorescence lifetime remained unchanged
(Figure S17). To correlate the fluorescence read-out with
concentration, we prepared varying concentrations of DL and
RhoB from 10 to 253 mM in agarose gels, which simulate
tissue samples (Figure S18). The fluorescence intensity in-
creased linearly with concentration for RhoB and DL (Fig-
ure 3E). The fluorescence lifetime of RhoB was almost
invariant to its concentration in the range up to 250 mM, in
agreement with literature data for RhoB.[24] However, DL
exhibited a shorter fluorescence lifetime with increasing DL
concentrations in the same concentration range (Figure 3 F
and Figure S18). Thus, in addition to FLIM-based visual-
ization, we can utilize the DL fluorescence intensity and
lifetime as a concentration measure in tissue. DL concen-
tration was calculated from the fluorescence intensity of the
FLIM images according to Equation (1):
cDL Ið Þ ¼
IROI= #pixel in ROI > image pixel
a
>MW> F r, ð1Þ
where IROI is the fluorescence intensity in the region of
interest (ROI), such as whole skin, viable epidermis or
dermis, MW is the molecular weight, and a and b are slope
and intercept of a linear fit of the concentration calibration
data (Figure S18) with b ¼ 0 for Equation (1). The FLIM
lifetime data were analyzed by a cluster algorithm,[5d, 8] which
allows us to separate image pixel according to discrete
lifetime clusters. We calculated the concentration from the
lifetime data using Equation (2):







total #pixel in ROI
>MW > Fr, ð2Þ
where tcluster is the mean fluorescence lifetime of a given
fluorescence cluster (see SI Experimental procedures) and
#pixelcluster are the corresponding number of pixels of this
cluster, a and b are slope and intercept of a linear fit to the
lifetime-based concentration calibration data (Figure S18).
For efficient DL penetration in skin, barrier disrupted
human skin was used whose stratum corneum was removed
Figure 4. Localization and quantification of DL in human skin by EPR
and FLIM. A) Sample preparation of skin after DL penetration, EPR
measured whole tissue blocks, while for FLIM measurements cryosec-
tions were used. B) Brightfield, C) fluorescence intensity, and D) FLIM
image with penetration profile. E) Fluorescence lifetime curves from
the FLIM cluster image in (D). The concentration calibration is shown
in Figure 3E,F and Figure S18. Comparison of DL concentration in
F) whole skin, G) viable epidermis (VE), and H) dermis (DE), deter-
mined by EPR and fluorescence lifetime and intensity from FLIM. Error
bars are : SD (n =4). I,J) DL concentrations from (G) and (H)
normalized to whole skin.
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by cyanoacrylate glue (Figure S19–20). Figure 4A depicts the
sample preparation for FLIM and EPR measurements. In
EPR, whole tissue blocks were measured, while cryosections
of the skin sample were used for FLIM measurements. The
EPR spectrum of DL in skin represents a superposition of
narrow and broad spectral lines, indicating that the DL
resides in different microenvironments in the skin. Fig-
ure 4B–D visualizes DL skin penetration using FLIM,
providing a spatially resolved image of DL distribution in
the tissue (Figure 4D). Cluster-FLIM enhances the image
contrast as well as statistical significance,[5d, 8] thereby resolv-
ing detailed skin structures (Figure 4D). The highest DL
concentration is depicted by the red fluorescence decay
cluster in the false-color coded image with the fastest
fluorescence decay time, while the lowest concentration is
shown in blue with the slowest fluorescence decay time
(Figure 4D, E). The concentration gradient from red to blue
as determined from the calibration (Figure S18) follows the
penetration profile, i.e., the highest concentration is found in
the upper layers of the viable epidermis (VE), while low but
significant concentrations are found in the dermis. As faster
fluorescence lifetimes are also found in filament-like struc-
tures in the dermis (DE), presumably collagen and elastin
fibers, we assume DL accumulation at these sites.
The absolute concentrations of DL in whole skin as well as
in the viable epidermis and dermis (cVE and cDE, respectively)
were quantified by EPR and FLIM (Figure 4F–H). Both
fluorescence-based methods are in good agreement with each
other and for each donor in whole skin. We found the
concentrations of DL in the skin based on EPR and
fluorescence approaches to be consistent with each other
within 2s, except for donor #3. At lower DL concentrations
within the dermis (Figure 4H), the fluorescence lifetime-
based concentration determination is in very good agreement
with EPR quantification. We also compared the relative
distribution of the DL concentration in the different skin
layers, i.e., viable epidermis and dermis, in a normalized plot
of concentration (Figure 4I, J). Here, the data reveal a very
good agreement between EPR and FLIM in the viable
epidermis for all three donors (Figure 4I). We estimated that
minimum concentrations in the lower mM to 100 nM range
can be determined from EPR and FLIM using the DL.[9e,25]
The apparent heterogeneous inter-donor penetration
behavior of donor #3 may be due to the fact that sample
penetration heterogeneities would be more pronounced in
cryosections, as used for FLIM, than in the integral concen-
tration determination in EPR (Figure 4A). Another reason
could be follicular penetration, which was so far unaccounted
for in the cryosections. As shown in Figure 5A,B, the
follicular and transfollicular penetration was significant (18-
fold higher concentration compared to surrounding tissue) for
the barrier disrupted skin used in this work. Compared to the
FLIM measurements on cryosections, the EPR measurements
on tissue blocks could involve DL accumulation within the
hair follicles and its surroundings. However, even if consid-
erably higher DL (Figure 5A, B) can be found in hair follicles,
they only contribute to 1–14% of the skin surface depending
on body site,[26] such that DL penetration would be increased
by about 5%. Thus, everything considered, our quantitative
results of DL skin penetration were consistent between EPR
and FLIM.
Besides spin label counting, EPR provides information
about the microenvironment of the spin label. Combined with
the high spatial resolution and contrast enhancement of
FLIM, we were also able to obtain details about the environ-
ment of the DL at the subcellular level. Figure 5C shows the
localization of the DL in the viable epidermis, both in the
intercellular space and the cytoplasm of keratinocytes, which
was verified in monolayer experiments (Figure S21). In the
dermis, collagens and elastins exhibit a notably strong DL
fluorescence signal, while DL was not identified in local skin
cells, i.e., fibroblasts or macrophages (Figure 5D). By simu-
lating the EPR spectrum (SI Experimental procedures,
Table S3), DL was found to be surrounded by two different
microenvironments (Figure 5 E).
In the first microenvironment, DL had a hyperfine
coupling constant (azz) of 100 MHz and a rotational correla-
tion time (tcorr) (see SI Experimental procedures)
[27] of 9 ns,
representing DL with low mobility in a slightly apolar
Figure 5. Sites of DL accumulation. A) Brightfield and B) FLIM images
of a hair follicle of the same ROI. C) The viable epidermis and D) the
dermis shown by FLIM. E) EPR spectrum of DL in whole skin is a linear
combination of pure spectra of DL in a hydrophilic, fast mobility
(DLHydro) or less polar, low mobility environment (LME). F) Experimen-
tal (solid lines) and simulated (dotted lines) EPR spectra of DL in the
viable epidermis (VE) and dermis (DE). All spectra were normalized to
the maximum peak intensity. The fraction of DLHydro and the corre-
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environment, compatible to a restricted microenvironment
with lipids, hydrophobic proteins, and less water content. In
the other microenvironment, DL had an azz of 105 MHz and
a smaller tcorr of 0.3–2 ns, indicating DL with high mobility in
a hydrophilic microenvironment (DLHydro). The tcorr of DLHydro
in the DE was shorter (0.3 ns) than in the VE (tcorr = 2 ns),
indicating a higher water content and thus enabling a higher
mobility. DLHydro was found with (4: 3)% in the viable
epidermis, and this fraction increased in the dermis (Fig-
ure 5F, Table S3). The less hydrophilic environment in the
viable epidermis is well in line with previous data.[28] Thus, the
environmental sensitivity of the spin label was compatible
with the main distribution of DL in the viable epidermis and
within dermal collagen, as shown by FLIM (Figure 5C, D).
Conclusion
This work realizes the functional chemical synthesis of
both a fluorophore and a spin marker into one compound,
that we call dual label. This strategy provides the possibility of
multiplexing FLIM and EPR in tissue investigations, for
example, in skin penetration experiments for drug delivery.
The amount of DL penetrating into different skin layers
quantified by FLIM was in very good agreement with EPR.
The spatial distribution of DL based on FLIM and its
visualized accumulation sites yields a holistic image of the
DL diffusion and interaction pattern when combined with
EPR spectra simulations of DLs microenvironment. This is,
for instance, of utmost importance when investigating anti-
cancer drugs in preclinical studies. 3D tissue models, for
example, tumor models to replace animal models, are getting
more important. Here, the dual label could be a valuable tool
to understand drug and carrier distribution which could give
information with respect to treatment efficiency and develop-
ment of treatment resistance; in particular, for macromolec-
ular drugs for which the penetration into tissue is critical. In-
depth insight into drug diffusivities and physical parameters
determining drug distribution in tissue[28] could be obtained in
the future from DL concentration data. Besides the quantifi-
cation and target detection in tissue and drug delivery, the
applications of combined FLIM and EPR measurements are
versatile and future applications are numerous. The DL
platform can be applied to any system, where spatial
resolution combined with knowledge about concentration
and local environment is required. For instance, the deacti-
vation of the EPR label could act as a sensor for the
production of reactive oxygen species,[29] while the FLIM
label allows the simultaneous localization of the DL within
the cellular environment.[30] Also, photodynamic therapy in
conjunction with the use of photosensitizers are feasible.[31]
Similarly, we envision the use of the DL compound in in vitro
experiments to provide new and unprecedented insight into
biomolecular dynamics, structure, and interactions. Thus, we
hope that this multi read-out labeling platform paves the way
for future studies in which the complementary information
from FLIM and EPR enables comprehensive characterization
of any target system.
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